Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Biguanides Market?

The size of the biguanides market has been experiencing consistent growth in the past few years. Projected to escalate from $4.96 billion in 2024 to $5.11 billion in 2025, this market is set to witness a compound annual growth rate (CAGR) of 3.1%. The historic period’s growth is mainly due to increased demand for oral hypoglycemic medications, surge in the elderly population, upturn in obesity figures, and heightened consciousness about managing diabetes.

The biguanides market is projected to experience consistent expansion in the coming years, achieving a size of “$5.81 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 3.2%.” The anticipated growth within this forecast period is being attributed to factors such as the rising acceptance of combination therapies, developments in medication delivery technology, escalated research and development investments, growing healthcare expenditures and the widening applicability in the treatment of polycystic ovary syndrome. The forecast period also reveals significant trends such as a heightened focus on the development of extended-release formulas, a growing inclination towards fixed-dose combination treatments, emerging applications in the field of oncology and the introduction of new biguanides with enhanced efficacy and safety profiles.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15735&type=smp

Which Factor Is Shaping The Future Of The Biguanides Market?

The anticipated upsurge in instances of diabetes is projected to further fuel the expansion of the biguanides market. Diabetes, a chronic metabolic ailment, is distinguished by elevated blood sugar levels due to the body’s insufficiency in insulin production. The escalation in diabetes instances is instigated by multiple factors such as modifications in lifestyle, an ageing population, genetic susceptibility, enhanced diagnostic methods, and external environmental influences. Biguanides, including metformin, help manage diabetes by ameliorating insulin receptiveness, diminishing liver’s glucose production, and reducing blood sugar levels in individuals affected by type 2 diabetes. For instance, the UK-based government department, Office for Health Improvement & Disparities, reported in March 2024 that between March 2022 and March 2023, there was a 22% increase in the percentage of individuals with type 1 diabetes receiving all eight recommended care procedures, and a 21% increase for type 2 diabetes, while the proportion reaching target HbA1c levels climbed to 37.9%, the most significant record. Thus, the escalating prevalence of diabetes bolsters the growth of the biguanides market.

The biguanides market covered in this report is segmented –

1) By Type: Metformin, Phenformin, Other Types

2) By Dosage Form: Tablets, Oral Solutions

3) By Formulation: Immediate Release, Extended Release

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

2) By Phenformin: Phenformin Hydrochloride

3) By Other Types: Buformin, Metformin Combinations

What Trends Are Currently Influencing Growth In The Biguanides Market?

In an attempt to provide better treatment, minimize adverse effects, and enhance patient compliance, key players in the biguanide market are concentrating on the development of innovative solutions such as extended-release biguanide medications. An extended-release biguanide drug gradually releases its main ingredient, providing a stable blood concentration and enhanced diabetic management for patients, thereby promoting adherence to the treatment regimen. For instance, Dr. Reddy’s Laboratories, a biotech firm from India, introduced saxagliptin and metformin hydrochloride extended-release medications in August 2023. This new medicine is a generic variant of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA), combining saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide. It’s formulated to boost blood sugar control in adults suffering from type 2 diabetes mellitus and should be taken in conjunction with the prescribed diet and exercise regime. The novel extended-release formula enhances patient adherence and its effectiveness.

Which Companies Hold The Largest Market Share In The Biguanides Sector?

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd., Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Shionogi & Co Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc., Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

https://www.thebusinessresearchcompany.com/report/biguanides-global-market-report

How Does Regional Performance Compare Across The Biguanides Industry?

Asia-Pacific was the largest region in the biguanides market in 2024. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15735&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model